BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1

Historical Holders from Q1 2021 to Q3 2025

Type / Class
Debt / NOTE 2.500% 3/1
All holders as of 30 Sep 2025
Q3 2025
Total 13F principal, excl. options
503,553,600
Holdings value
$706,927,628
% of all portfolios
0.001%
Number of holders
45
Number of buys
15
Number of sells
-20
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1

Period Principal Value Change Price Investors
2025 Q3 503,553,600 $706,927,628 -$1,701,713 $1.4 45
2025 Q2 562,169,600 $702,425,663 +$36,426,925 $1.25 44
2025 Q1 574,937,600 $656,979,517 +$27,477,843 $1.14 44
2024 Q4 562,886,600 $590,898,608 -$57,357,159 $1.05 43
2024 Q3 580,126,900 $598,911,587 +$11,941,965 $1.03 42
2024 Q2 569,382,900 $575,758,559 +$8,898,618 $1.01 41
2024 Q1 560,289,110 $603,033,697 +$6,351,656 $1.08 40
2023 Q4 553,225,000 $670,007,473 +$16,902,300 $1.21 45
2023 Q3 544,512,610 $527,468,975 +$46,272,601 $0.9609 41
2023 Q2 508,797,285 $400,809,379 -$17,145,882 $0.783 33
2023 Q1 24,428,285 $29,769,764 -$9,378,870 $73.29 5
2022 Q4 532,657,035 $235,817,609 -$942,915 $0.45 31
2022 Q3 391,715,535 $242,598,365 +$158,207 $0.5928 31
2022 Q2 403,210,035 $228,835,958 -$80,860,371 $0.546 31
2022 Q1 546,513,489 $332,288,737 -$4,271,771 $0.5889 33
2021 Q4 522,000,515 $380,362,858 -$37,345,964 $0.7322 38
2021 Q3 532,460,742 $739,286,875 -$47,139,012 $1.38 40
2021 Q2 570,332,000 $936,089,296 +$76,483,812 $1.64 39
2021 Q1 519,285,000 $858,858,248 +$842,687,530 $1.65 35